SciClone (SCLN) Ends Cancer Treatment Trials
October 5, 2009 · Filed Under R&D
SciCLone Pharmaceuticals (SCLN) announced the discontinuation of the investigational treatments under its randomized, placebo-controlled, double-blind Phase 2 trial that is evaluating RP101 — a nucleoside analog known as BvdU — for the treatment of late-stage pancreatic cancer. This decision followed the recommendation of the Data Safety Monitoring Committee (DSMC) with oversight responsibility for this clinical trial that was based upon the data reviewed at the most recent DSMC meeting. Further details will be reported when these data have been unblinded and reviewed by SciClone.
Its shares are down 13% to $3.61.
Douglas A. McIntyre
